Bleeding Disorders Treatment Market
Bleeding Disorders Treatment Market Analysis By Type (Hemophilia A, Hemophilia B), By Drug Class (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants), and By Region - Global Market Insights 2021 to 2027
Analysis of Bleeding Disorders Treatment market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Bleeding Disorders Treatment Market Outlook (2021 to 2027)
The global bleeding disorders treatment market reached a valuation of US$ 12.7 Billion in 2020, and this industry is expected to rise at a high CAGR of 6.7% to reach US$ 19.9 Billion by the end of 2027.
The hemophilia A disease segment is projected to increase at 6.6% CAGR from 2021 to 2027. Rising awareness about the effectiveness of hemophilia A medicines is driving the complementing market growth.
| Report Attributes | Details |
|---|---|
| Market Size (2020) | US$ 12.7 Billion |
| Projected Year Value (2027) | US$ 19.9 Billion |
| Global Market Growth Rate (2021 to 2027) | 6.7% CAGR |
| China Market Growth Rate (2021 to 2027) | 10.1% |
| Key Companies Profiled | Bayer AG; CSL Behring; Grifols International SA; Novo Nordisk A/S; Octapharma AG; Pfizer, Inc. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Revenue Analysis of Bleeding Disorders Treatment from 2017 to 2020 Vs Market Outlook for 2021 to 2027
“Growing Awareness of Bleeding Disorders across the World”
As per Fact.MR, a market research and competitive intelligence provider, the global market for bleeding disorders treatment was valued at US$ 12.7 Bn in 2020.
A bleeding disorder is a medical illness in which blood coagulation is disrupted, preventing a blood clot from forming. Internal and exterior bleeding diseases are both possible. When a person sustains an injury, blood pours out of the body. Internal bleeding occurs when blood continues to flow beneath the skin, similar to a clot in the brain.
In hemophilic individuals or people with other bleeding disorders, a bleeding disease impairs the process of blood coagulation by blocking the formation of blood clots. The majority of these bleeding problems are hereditary, although others can be acquired as a result of liver disease, pharmaceutical side effects, low red blood cell count, vitamin K insufficiency, and other factors.
A major driver for the expansion of the global bleeding disorders treatment market is high investments in R&D activities pertaining to the creation of recombinant factors, along with advances in the technology utilized to treat bleeding disorders among patients.
Considering these factors, the market is projected to witness high growth over the forecast period, registering a CAGR of 6.7% to reach US$ 19.9 Billion by 2027.
Which Factors Can Positively Influence Demand for Bleeding Disorders Treatment Medications?
“Growing Prevalence of Bleeding Disorders and Advancements in Treatments to Bolster Market Revenue”
The market for bleeding disorders treatment is being driven by an increase in the number of people with bleeding disorders. More than 1,125,000 males worldwide have a genetic bleeding problem, with 418,000 having a mild form of the disease that is typically undetected. Because a huge number of patients are being treated in some way, the market for bleeding disorders treatment has been rising.
Many corporations and scientific institutes have been working to develop new drugs and improve existing ones in order to boost patient awareness of therapy and adoption rates.
Many replacement medications now have easier delivery methods, lower immunogenicity, higher potency, and longer half-lives. For the past five years, bioengineering advancements have aided in the treatment of bleeding diseases. The bleeding disorders treatment market is expected to rise as a result of these developments over the coming years.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What Restraints are Being Faced by Bleeding Disorders Treatment Providers?
“Shortage of Clinicians & Unfavorable Reimbursement Situation Hampering Market Growth”
The high cost of treatment is a major roadblock in the bleeding disorders treatment market. Daily outpatient appointments, hospitalization, and lab testing all have prohibitively high prices. Other issues, such as a lack of knowledge in some developing nations, are projected to stymie the expansion of the market for acquired bleeding disorders treatments.
The dearth of skilled specialists and trained expertise would pose a significant barrier to the expansion of the bleeding disorders treatment market. The market's growth pace will be slowed by a lack of access to adequate treatment due to high prescription costs. The scope of growth will also be limited by a lack of favorable reimbursement policies.
Which Region is Expected to Lead the Global Bleeding Disorders Treatment Market?
“Accessibility to Healthcare Facilities to Propel Industry Expansion in North America”
North America is expected to lead the worldwide bleeding disorders treatment market because of its affordability and accessibility to healthcare facilities. The expansion of the market is aided by patient awareness of bleeding disorders, as well as government and private-sector treatment programs.
The market in the region is the quick continued development of enterprises working in the drug industry due to the early stage acceptance of established medical technologies. Because of the rising prevalence of various blood diseases and increased awareness among the patient population in this area, North America is likely to hold a significant market share in the blood disorders therapeutics market.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Country-wise Insights
Will the U.S. Bleeding Disorders Treatment Market Exhibit Steady Growth?
“Favorable Reimbursement & Insurance Policies Boosting Market Value”
The U.S. bleeding disorders treatment market was valued at US$ 3.4 Bn in 2020 and is expected to rise at a significant CAGR over the forecast period. According to the World Federation of Hemophilia, over 18 thousand persons in the United States have hemophilia and over 11 thousand people have Von Willebrand Disease (VWD). Hemophilia A affects 1 in every 5,000 male births, and about 400 kids are born with the disease each year.
Expansion of the bleeding disorders treatment market in the United States is aided by factors such as high rates of bleeding disorders along with favorable reimbursement and insurance policies.
Moreover, rising investments in research & development to create treatment options for blood disorders, as well as the availability of well-established healthcare infrastructure, are driving the market expansion.
Why is Demand for Bleeding Disorders Treatment Systems Surging in China?
“Rapid Availability of Drugs & Treatments Driving China Market Growth”
China, the world's second-largest economy, is expected to reach a projected market size of US$ 4.3 Bn by 2027, representing a 10.1% CAGR from 2021 to 2027. The market in China is likely to have a big revenue share in the bleeding disorders treatment market because people are becoming more aware of hereditary diseases.
Rising occurrence of bleeding disorders among patients and the availability of drugs or treatments to address these illnesses are driving market growth. The market In China is likely to benefit from factors such as increased R&D efforts and pharmaceutical companies' increased focus on creating novel drugs.
Category-wise Insights
Which Bleeding Disorders Treatment Type is Expected to Showcase Highest Growth?
“Rising R&D Expenditure on Hemophilia A Drugs & Treatments Driving Market Growth”
The hemophilia A disease segment is expected to rise at a 6.6% CAGR and reach US$ 11.1 Bn over the forecast period. The bleeding disorders treatment market is divided into hemophilia A, hemophilia B, and other forms based on type. The increased number of patients with hemophilia A and rising R&D expenditure on hemophilia medicines are driving market expansion.
The hemophilia A segment dominated the bleeding disorder treatment market in the past, and this trend is expected to continue over the forecast period. This is due to an increase in the prevalence of bleeding disorders, as well as an increase in the availability of hemophilia treatment and medications in the global hemophilia treatment market.
Which Drug Class is Expected to Gain Momentum?
“Recombinant Coagulation Factor Concentrates Gaining Traction Due to Increasing Need to Treat Blood-related Disorders”
The recombinant coagulation factor concentrates segment is predicted to increase at the fastest rate in the market. This increase can be ascribed to increased R&D activities and pharmaceutical companies' increased attention to recombinant goods, which has resulted in the launch of new medications.
Primary drivers of the segment are the rising prevalence of blood diseases and the increasing acceptance of recombinant coagulation factor concentrates. In the treatment of illnesses such as hemophilia, recombinant coagulation factor concentrates are employed (prevention and control of hemorrhagic episodes).
Competitive Landscape
The blood disorders treatment market is competitive and fragmented, with a number of prominent companies operating in this space. In terms of market share, the industry is currently dominated by a few significant competitors.
For instance,
- In November 2020, Pfizer announced the start of the Phase III BASIS study of marstacimab, an experimental treatment for treating persons with severe hemophilia A or B. The U.S. Food and Drug Administration (FDA) granted it fast track status for use in combination with inhibitors as a potential treatment for hemophilia A and B.
Key Segments of Bleeding Disorders Treatment Industry Research
-
By Type :
- Hemophilia A
- Hemophilia B
- Other Types
-
By Drug Class :
- Plasma-derived Coagulation Factor Concentrates
- Recombinant Coagulation Factor Concentrates
- Fibrin Sealants
- Other Drug Classes
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Key Success Factors
- 5. Market Background
- 7. Global Market Volume (Units) Analysis 2017 to 2020 and Forecast, 2021 to 2027
- 8. Global Market - Pricing Analysis
- 9. Global Market Value Analysis 2017 to 2020 and Forecast, 2021 to 2027
- 10. Global Market Analysis 2017 to 2020 and Forecast 2021 to 2027, by Type
- 10.1. Hemophilia A
- 10.2. Hemophilia B
- 10.3. Other Types
- 11. Global Market Analysis 2017 to 2020 and Forecast 2021 to 2027, by Drug Class
- 11.1. Plasma-derived Coagulation Factor Concentrates
- 11.2. Recombinant Coagulation Factor Concentrates
- 11.3. Fibrin Sealants
- 11.4. Other Drug Classes
- 12. Global Market Analysis 2017 to 2020 and Forecast 2021 to 2027, by Region
- 12.1. North America
- 12.2. Latin America
- 12.3. Europe
- 12.4. East Asia
- 12.5. South Asia
- 12.6. Oceania
- 12.7. Middle East and Africa (MEA)
- 13. North America Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 14. Latin America Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 15. Europe Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 16. South Asia Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 17. East Asia Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 18. Oceania Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 19. Middle East and Africa Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 20. Key and Emerging Countries Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 21. Market Structure Analysis
- 22. Competition Analysis
- 22.1. Bayer AG
- 22.2. CSL Behring
- 22.3. Grifols International SA
- 22.4. Novo Nordisk A/S
- 22.5. Octapharma AG
- 22.6. Pfizer, Inc.
- 23. Assumptions and Acronyms Used
- 24. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Volume (‘000 Units) Analysis and Opportunity Assessment 2017 to 2027, By Type
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Type
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Drug Class
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Region
Table 05: North America Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2031, By Country
Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Type
Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Drug Class
Table 08: Latin America Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2031, By Country
Table 09: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Type
Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Drug Class
Table 11: Europe Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2031, By Country
Table 12: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Type
Table 13: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Drug Class
Table 14: South Asia Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2031, By Country
Table 15: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Type
Table 16: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Drug Class
Table 17: East Asia Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2031, By Country
Table 18: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Type
Table 19: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Drug Class
Table 20: Oceania Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2031, By Country
Table 21: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Type
Table 22: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Drug Class
Table 23: Middle East and Africa Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2031, By Country
Table 24: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Type
Table 25: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Drug Class
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Volume (in 000' Units) Analysis, 2017 to 2020
Figure 02: Global Market Volume Forecast (in 000' Units), 2021 to 2027
Figure 03: Pricing Analysis (US$) Per Product, By Region, 2020
Figure 04: Pricing Analysis (US$) Per Product, By Region, 2020
Figure 05: Global Market Value Analysis (US$ Mn), 2017 to 2020
Figure 06: Global Market Value Forecast (US$ Mn), 2021 to 2027
Figure 07: Global Market Absolute $ Opportunity, 2021 to 2027
Figure 08: Global Market Share Analysis (%), By Type, 2021 to 2027
Figure 09: Global Market Y-o-Y Analysis (%), By Type, 2021 to 2027
Figure 10: Global Market Attractiveness Analysis by Type, 2021 to 2027
Figure 11: Global Market Share Analysis (%), By Drug Class, 2021 to 2027
Figure 12: Global Market Y-o-Y Analysis (%), By Drug Class, 2021 to 2027
Figure 13: Global Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 14: Global Market Share Analysis (%), By Region, 2021 to 2027
Figure 15: Global Market Y-o-Y Analysis (%), By Region, 2021 to 2027
Figure 16: Global Market Attractiveness Analysis by Region, 2021 to 2027
Figure 17: North America Market Value Share, By Type, 2021 (E)
Figure 18: North America Market Value Share, By Drug Class, 2021 (E)
Figure 19: North America Market Value Share, By Country, 2021 (E)
Figure 20: North America Market Value Analysis (US$ Mn), 2017 to 2020
Figure 21: North America Market Value Forecast (US$ Mn), 2021 to 2027
Figure 22: North America Market Attractiveness Analysis by Type, 2021 to 2027
Figure 23: North America Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 24: North America Market Attractiveness Analysis by Country, 2021 to 2027
Figure 25: Latin America Market Value Share, By Type, 2021 (E)
Figure 26: Latin America Market Value Share, By Drug Class, 2021 (E)
Figure 27: Latin America Market Value Share, By Country, 2021 (E)
Figure 28: Latin America Market Value Analysis (US$ Mn), 2017 to 2020
Figure 29: Latin America Market Value Forecast (US$ Mn), 2021 to 2027
Figure 30: Latin America Market Attractiveness Analysis by Type, 2021 to 2027
Figure 31: Latin America Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 32: Latin America Market Attractiveness Analysis by Country, 2021 to 2027
Figure 33: Europe Market Value Share, By Type, 2021 (E)
Figure 34: Europe Market Value Share, By Drug Class, 2021 (E)
Figure 35: Europe Market Value Share, By Country, 2021 (E)
Figure 36: Europe Market Value Analysis (US$ Mn), 2017 to 2020
Figure 37: Europe Market Value Forecast (US$ Mn), 2021 to 2027
Figure 38: Europe Market Attractiveness Analysis by Type, 2021 to 2027
Figure 39: Europe Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 40: Europe Market Attractiveness Analysis by Country, 2021 to 2027
Figure 41: South Asia Market Value Share, By Type, 2021 (E)
Figure 42: South Asia Market Value Share, By Drug Class, 2021 (E)
Figure 43: South Asia Market Value Share, By Country, 2021 (E)
Figure 44: South Asia Market Value Analysis (US$ Mn), 2017 to 2020
Figure 45: South Asia Market Value Forecast (US$ Mn), 2021 to 2027
Figure 46: South Asia Market Attractiveness Analysis by Type, 2021 to 2027
Figure 47: South Asia Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 48: South Asia Market Attractiveness Analysis by Country, 2021 to 2027
Figure 49: East Asia Market Value Share, By Type, 2021 (E)
Figure 50: East Asia Market Value Share, By Drug Class, 2021 (E)
Figure 51: East Asia Market Value Share, By Country, 2021 (E)
Figure 52: East Asia Market Value Analysis (US$ Mn), 2017 to 2020
Figure 53: East Asia Market Value Forecast (US$ Mn), 2021 to 2027
Figure 54: East Asia Market Attractiveness Analysis by Type, 2021 to 2027
Figure 55: East Asia Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 56: East Asia Market Attractiveness Analysis by Country, 2021 to 2027
Figure 57: Oceania Market Value Share, By Type, 2021 (E)
Figure 58: Oceania Market Value Share, By Drug Class, 2021 (E)
Figure 59: Oceania Market Value Share, By Country, 2021 (E)
Figure 60: Oceania Market Value Analysis (US$ Mn), 2017 to 2020
Figure 61: Oceania Market Value Forecast (US$ Mn), 2021 to 2027
Figure 62: Oceania Market Attractiveness Analysis by Type, 2021 to 2027
Figure 63: Oceania Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 64: Oceania Market Attractiveness Analysis by Country, 2021 to 2027
Figure 65: Middle East and Africa Market Value Share, By Type, 2021 (E)
Figure 66: Middle East and Africa Market Value Share, By Drug Class, 2021 (E)
Figure 67: Middle East and Africa Market Value Share, By Country, 2021 (E)
Figure 68: Middle East and Africa Market Value Analysis (US$ Mn), 2017 to 2020
Figure 69: Middle East and Africa Market Value Forecast (US$ Mn), 2021 to 2027
Figure 70: Middle East and Africa Market Attractiveness Analysis by Type, 2021 to 2027
Figure 71: Middle East and Africa Market Attractiveness Analysis by Drug Class, 2021 to 2027
Figure 72: Middle East and Africa Market Attractiveness Analysis by Country, 2021 to 2027
Figure 73: U. S. Market Value Analysis (US$ Mn), 2021 & 2031
Figure 74: U. S. Market Value Share, By Type, 2021 (E)
Figure 75: U. S. Market Value Share, By Drug Class, 2021 (E)
Figure 76: Canada Market Value Analysis (US$ Mn), 2021 & 2031
Figure 77: Canada Market Value Share, By Type, 2021 (E)
Figure 78: Canada Market Value Share, By Drug Class, 2021 (E)
Figure 79: Mexico Market Value Analysis (US$ Mn), 2021 & 2031
Figure 80: Mexico Market Value Share, By Type, 2021 (E)
Figure 81: Mexico Market Value Share, By Drug Class, 2021 (E)
Figure 82: Brazil Market Value Analysis (US$ Mn), 2021 & 2031
Figure 83: Brazil Market Value Share, By Type, 2021 (E)
Figure 84: Brazil Market Value Share, By Drug Class, 2021 (E)
Figure 85: U. K. Market Value Analysis (US$ Mn), 2021 & 2031
Figure 86: U. K. Market Value Share, By Type, 2021 (E)
Figure 87: U. K. Market Value Share, By Drug Class, 2021 (E)
Figure 88: Germany Market Value Analysis (US$ Mn), 2021 & 2031
Figure 89: Germany Market Value Share, By Type, 2021 (E)
Figure 90: Germany Market Value Share, By Drug Class, 2021 (E)
Figure 91: France Market Value Analysis (US$ Mn), 2021 & 2031
Figure 92: France Market Value Share, By Type, 2021 (E)
Figure 93: France Market Value Share, By Drug Class, 2021 (E)
Figure 94: Italy Market Value Analysis (US$ Mn), 2021 & 2031
Figure 95: Italy Market Value Share, By Type, 2021 (E)
Figure 96: Italy Market Value Share, By Drug Class, 2021 (E)
Figure 97: Spain Market Value Analysis (US$ Mn), 2021 & 2031
Figure 98: Spain Market Value Share, By Type, 2021 (E)
Figure 99: Spain Market Value Share, By Drug Class, 2021 (E)
Figure 100: Russia Market Value Analysis (US$ Mn), 2021 & 2031
Figure 101: Russia Market Value Share, By Type, 2021 (E)
Figure 102: Russia Market Value Share, By Drug Class, 2021 (E)
Figure 103: China Market Value Analysis (US$ Mn), 2021 & 2031
Figure 104: China Market Value Share, By Type, 2021 (E)
Figure 105: China Market Value Share, By Drug Class, 2021 (E)
Figure 106: Japan Market Value Analysis (US$ Mn), 2021 & 2031
Figure 107: Japan Market Value Share, By Type, 2021 (E)
Figure 108: Japan Market Value Share, By Drug Class, 2021 (E)
Figure 109: South Korea Market Value Analysis (US$ Mn), 2021 & 2031
Figure 110: South Korea Market Value Share, By Type, 2021 (E)
Figure 111: South Korea Market Value Share, By Drug Class, 2021 (E)
Figure 112: India Market Value Analysis (US$ Mn), 2021 & 2031
Figure 113: India Market Value Share, By Type, 2021 (E)
Figure 114: India Market Value Share, By Drug Class, 2021 (E)
Figure 115: ASEAN Market Value Analysis (US$ Mn), 2021 & 2031
Figure 116: ASEAN Market Value Share, By Type, 2021 (E)
Figure 117: ASEAN Market Value Share, By Drug Class, 2021 (E)
Figure 118: Australia Market Value Analysis (US$ Mn), 2021 & 2031
Figure 119: Australia Market Value Share, By Type, 2021 (E)
Figure 120: Australia Market Value Share, By Drug Class, 2021 (E)
Figure 121: New Zealand Market Value Analysis (US$ Mn), 2021 & 2031
Figure 122: New Zealand Market Value Share, By Type, 2021 (E)
Figure 123: New Zealand Market Value Share, By Drug Class, 2021 (E)
Figure 124: GCC Countries Market Value Analysis (US$ Mn), 2021 & 2031
Figure 125: GCC Countries Market Value Share, By Type, 2021 (E)
Figure 126: GCC Countries Market Value Share, By Drug Class, 2021 (E)
Figure 127: Turkey Market Value Analysis (US$ Mn), 2021 & 2031
Figure 128: Turkey Market Value Share, By Type, 2021 (E)
Figure 129: Turkey Market Value Share, By Drug Class, 2021 (E)
Figure 130: South Africa Market Value Analysis (US$ Mn), 2021 & 2031
Figure 131: South Africa Market Value Share, By Type, 2021 (E)
Figure 132: South Africa Market Value Share, By Drug Class, 2021 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the sales forecast for bleeding disorders treatment?
The global market for bleeding disorders treatment is expected to be valued at US$ 19.9 Billion by 2027.
Which key growth strategies are driving bleeding disorders treatment market expansion?
Increasing prevalence of bleeding disorders and rising research and development initiatives for related treatments are driving market growth.
What was the market value for bleeding disorders treatment in 2021?
The global bleeding disorders treatment market was valued at US$ 13.5 Bn in 2021.
Which are the top 5 countries driving demand for bleeding disorders treatment products?
The U.S., Canada, Japan, China, and South Korea are expected to drive the most demand for bleeding disorders treatment products.
Who are the prominent bleeding disorders treatment equipment and drug providers?
Bayer AG, CSL Behring, Grifols International SA, Novo Nordisk A/S, and Octapharma AG are prominent bleeding disorders treatment equipment and medication providers.
Bleeding Disorders Treatment Market